Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Breast Cancer
    July 2018
  1. OKUMATSU K, Tsujimoto T, Wakaba K, Seki A, et al
    Effects of a combined exercise plus diet program on cardiorespiratory fitness of breast cancer patients.
    Breast Cancer. 2018 Jul 10. pii: 10.1007/s12282-018-0889.
    >> Share

  2. MA D, Chen C, Wu J, Wang H, et al
    Up-regulated lncRNA AFAP1-AS1 indicates a poor prognosis and promotes carcinogenesis of breast cancer.
    Breast Cancer. 2018 Jul 5. pii: 10.1007/s12282-018-0891.
    >> Share

  3. TOKUNAGA E, Fujita A, Takizawa K, Baba K, et al
    CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2018 Jul 3. pii: 10.1007/s12282-018-0888.
    >> Share

    June 2018
  4. PENG X, Yan B, Shen Y
    MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1.
    Breast Cancer. 2018 Jun 27. pii: 10.1007/s12282-018-0881.
    >> Share

  5. LIU L, Yin B, Yi Z, Liu X, et al
    Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs.
    Breast Cancer. 2018 Jun 14. pii: 10.1007/s12282-018-0880.
    >> Share

  6. TAKABATAKE D, Kajiwara Y, Ohtani S, Itano Y, et al
    The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.
    Breast Cancer. 2018 Jun 11. pii: 10.1007/s12282-018-0877.
    >> Share

  7. TOYAMA T, Yoshimura A, Hayashi T, Kobayashi N, et al
    A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
    Breast Cancer. 2018 Jun 8. pii: 10.1007/s12282-018-0879.
    >> Share

    May 2018
  8. LOUHICHI T, Ziadi S, Saad H, Dhiab MB, et al
    Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer.
    Breast Cancer. 2018 May 29. pii: 10.1007/s12282-018-0875.
    >> Share

  9. SAJI S
    The long and winding road for overcoming resistance to hormone therapy in breast cancer.
    Breast Cancer. 2018 May 28. pii: 10.1007/s12282-018-0876.
    >> Share

  10. GAO L, Li SC
    Cost-effectiveness analysis of lipegfilgrastim as primary prophylaxis in women with breast cancer in Australia: a modelled economic evaluation.
    Breast Cancer. 2018 May 25. pii: 10.1007/s12282-018-0872.
    >> Share

  11. WEN L, Liu L, Wen L, Yu T, et al
    Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0873.
    >> Share

  12. OSTAPCHUK YO, Perfilyeva YV, Kustova EA, Urazalieva NT, et al
    Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients.
    Breast Cancer. 2018 May 24. pii: 10.1007/s12282-018-0874.
    >> Share

  13. LEE SB, Sohn G, Kim J, Chung IY, et al
    Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study.
    Breast Cancer. 2018 May 21. pii: 10.1007/s12282-018-0869.
    >> Share

  14. TAKADA M, Takeuchi M, Suzuki E, Sato F, et al
    Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence.
    Breast Cancer. 2018 May 9. pii: 10.1007/s12282-018-0868.
    >> Share

  15. JAMAN MS, Sayeed MA
    Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives.
    Breast Cancer. 2018 May 3. pii: 10.1007/s12282-018-0866.
    >> Share

    April 2018
  16. KWAPISZ D
    Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0864.
    >> Share

  17. SAKAI H, Tsurutani J, Iwasa T, Komoike Y, et al
    HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
    Breast Cancer. 2018 Apr 26. pii: 10.1007/s12282-018-0861.
    >> Share

  18. WANG NN, Yang ZJ, Wang X, Chen LX, et al
    A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0863.
    >> Share

  19. AOYAGI T, Takabe K, Tamanuki T, Matsubara H, et al
    Pseudocirrhosis after chemotherapy in breast cancer, case reports.
    Breast Cancer. 2018 Apr 25. pii: 10.1007/s12282-018-0865.
    >> Share

  20. OHASHI R, Nagao M, Nakamura I, Okamoto T, et al
    Improvement in diagnostic performance of breast cancer: comparison between conventional digital mammography alone and conventional mammography plus digital breast tomosynthesis.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0859.
    >> Share

  21. NAZARI SS, Mukherjee P
    An overview of mammographic density and its association with breast cancer.
    Breast Cancer. 2018 Apr 12. pii: 10.1007/s12282-018-0857.
    >> Share

  22. LI Q, Gao H, Zhou S, Liao Y, et al
    LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-beta1 and downregulating PHGDH.
    Breast Cancer. 2018 Apr 6. pii: 10.1007/s12282-018-0858.
    >> Share

  23. IWASE M, Sawaki M, Hattori M, Yoshimura A, et al
    Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery.
    Breast Cancer. 2018 Apr 4. pii: 10.1007/s12282-018-0856.
    >> Share

    March 2018
  24. SASADA S, Shien T, Iwata H
    Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.
    Breast Cancer. 2018 Mar 23. pii: 10.1007/s12282-018-0855.
    >> Share

  25. WAKABAYASHI H, Hamaguchi T, Nagao N, Kato S, et al
    Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line.
    Breast Cancer. 2018 Mar 19. pii: 10.1007/s12282-018-0853.
    >> Share

  26. ZHANG JM, Wei K, Jiang M
    OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.
    Breast Cancer. 2018 Mar 13. pii: 10.1007/s12282-018-0844.
    >> Share

  27. YOSHIMURA A, Okumura S, Sawaki M, Hattori M, et al
    Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Breast Cancer. 2018 Mar 8. pii: 10.1007/s12282-018-0850.
    >> Share

  28. KA WH, Cho SK, Chun BN, Byun SY, et al
    The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
    Breast Cancer. 2018 Mar 7. pii: 10.1007/s12282-018-0849.
    >> Share

    February 2018
  29. RAMOS-ESQUIVEL A, Hernandez-Steller H, Savard MF, Landaverde DU, et al
    Cyclin-dependent kinase 4/6 inhibitors as first-line treatment for post-menopausal metastatic hormone receptor-positive breast cancer patients: a systematic review and meta-analysis of phase III randomized clinical trials.
    Breast Cancer. 2018 Feb 22. pii: 10.1007/s12282-018-0848.
    >> Share

  30. NOGUCHI S, Ellis MJ, Robertson JFR, Thirlwell J, et al
    Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
    Breast Cancer. 2018 Feb 15. pii: 10.1007/s12282-018-0838.
    >> Share

  31. MASUDA N, Toi M, Yamamoto N, Iwata H, et al
    Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicent
    Breast Cancer. 2018 Feb 14. pii: 10.1007/s12282-018-0839.
    >> Share

  32. CHEN W, Lv X, Xu X, Gao X, et al
    Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer.
    Breast Cancer. 2018 Feb 13. pii: 10.1007/s12282-018-0846.
    >> Share

  33. OHTANI S, Nakayama T, Yoshinami T, Watanabe KI, et al
    Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
    Breast Cancer. 2018 Feb 12. pii: 10.1007/s12282-018-0843.
    >> Share

  34. SURYAVANSHI M, Mehta A, Jaipuria J, Kumar D, et al
    Clinical utility of RT-PCR in assessing HER 2 gene expression versus traditional IHC and FISH in breast cancer patients.
    Breast Cancer. 2018 Feb 9. pii: 10.1007/s12282-018-0840.
    >> Share

  35. ZOU L, Liu FH, Shen PP, Hu Y, et al
    The incidence and risk factors of related lymphedema for breast cancer survivors post-operation: a 2-year follow-up prospective cohort study.
    Breast Cancer. 2018 Feb 3. pii: 10.1007/s12282-018-0830.
    >> Share

  36. IWATA H
    Clinical development of CDK4/6 inhibitor for breast cancer.
    Breast Cancer. 2018 Feb 1. pii: 10.1007/s12282-017-0827.
    >> Share

    January 2018
  37. WANG Y, Wang J, Long F, Wang N, et al
    Correlation of FANCM expression with clinical factors in luminal B breast cancer.
    Breast Cancer. 2018 Jan 31. pii: 10.1007/s12282-018-0841.
    >> Share

  38. KHAN RT, Siddique A, Shahid N, Khokher S, et al
    Breast cancer risk associated with genes encoding DNA repair MRN complex: a study from Punjab, Pakistan.
    Breast Cancer. 2018 Jan 24. pii: 10.1007/s12282-018-0837.
    >> Share

  39. NGUYEN-THU H, Hanaoka H, Nakajima T, Yamaguchi A, et al
    Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and (18)F-FDG-PET.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0834.
    >> Share

  40. OZAKI Y, Tanabe Y, Tamura N, Ogura T, et al
    Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
    Breast Cancer. 2018 Jan 22. pii: 10.1007/s12282-018-0836.
    >> Share

  41. YANG ZJ, Yu Y, Chi JR, Guan M, et al
    The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual.
    Breast Cancer. 2018 Jan 20. pii: 10.1007/s12282-018-0833.
    >> Share

  42. HABYARIMANA T, Attaleb M, Mazarati JB, Bakri Y, et al
    Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients.
    Breast Cancer. 2018 Jan 19. pii: 10.1007/s12282-018-0831.
    >> Share

  43. INARI H, Shimizu S, Suganuma N, Yoshida T, et al
    Correction to: A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women.
    Breast Cancer. 2018 Jan 10. pii: 10.1007/s12282-018-0832.
    >> Share

  44. PIVOT X, Im SA, Guo M, Marme F, et al
    Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
    Breast Cancer. 2018 Jan 4. pii: 10.1007/s12282-017-0826.
    >> Share

    December 2017
  45. PIERRISNARD C, Baciuchka M, Mancini J, Rathelot P, et al
    Body image and psychological distress in women with breast cancer: a French online survey on patients' perceptions and expectations.
    Breast Cancer. 2017 Dec 29. pii: 10.1007/s12282-017-0828.
    >> Share

  46. ATTALLAH AM, El-Far M, Abdelrazek MA, Omran MM, et al
    HCV nonstructural protein 4 is associated with aggressiveness features of breast cancer.
    Breast Cancer. 2017 Dec 28. pii: 10.1007/s12282-017-0829.
    >> Share

  47. SHIMOI T, Yoshida M, Kitamura Y, Yoshino T, et al
    TERT promoter hotspot mutations in breast cancer.
    Breast Cancer. 2017 Dec 8. pii: 10.1007/s12282-017-0825.
    >> Share

  48. TSUDA B, Miyamoto A, Yokoyama K, Ogiya R, et al
    B-cell populations are expanded in breast cancer patients compared with healthy controls.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0824.
    >> Share

  49. DORFEL S, Steffens CC, Meyer D, Tesch H, et al
    Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
    Breast Cancer. 2017 Dec 4. pii: 10.1007/s12282-017-0823.
    >> Share

  50. HE J, Chen Y, Cai L, Li Z, et al
    UBAP2L silencing inhibits cell proliferation and G2/M phase transition in breast cancer.
    Breast Cancer. 2017 Dec 1. pii: 10.1007/s12282-017-0820.
    >> Share

    November 2017
  51. INOUE H, Horii R, Ito Y, Iwase T, et al
    Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Breast Cancer. 2017 Nov 28. pii: 10.1007/s12282-017-0822.
    >> Share

  52. ZHANG ZL, Jiang QC, Wang SR
    Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
    Breast Cancer. 2017 Nov 27. pii: 10.1007/s12282-017-0821.
    >> Share

  53. ZHAO Q, Song W, He DY, Li Y, et al
    Identification of key gene modules and pathways of human breast cancer by co-expression analysis.
    Breast Cancer. 2017 Nov 23. pii: 10.1007/s12282-017-0817.
    >> Share

  54. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Nov 20. doi: 10.1007/s12282-017-0815.
    >> Share

  55. KASSEM L, Shohdy KS, Lasheen S, Abdel-Rahman O, et al
    Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis.
    Breast Cancer. 2017 Nov 16. doi: 10.1007/s12282-017-0818.
    >> Share

  56. WANG R, Li J, Zhao Y, Li Y, et al
    Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
    Breast Cancer. 2017 Nov 14. doi: 10.1007/s12282-017-0816.
    >> Share

  57. ADHAMI M, Haghdoost AA, Sadeghi B, Malekpour Afshar R, et al
    Candidate miRNAs in human breast cancer biomarkers: a systematic review.
    Breast Cancer. 2017 Nov 3. doi: 10.1007/s12282-017-0814.
    >> Share

  58. SHIGEMATSU H, Ozaki S, Yasui D, Zaitsu J, et al
    Comparison of CK-IHC assay on serial frozen sections, the OSNA assay, and in combination for intraoperative evaluation of SLN metastases in breast cancer.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0811.
    >> Share

  59. HARAO M, Ando J, Kamata H, Hoshi N, et al
    Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
    Breast Cancer. 2017 Nov 1. doi: 10.1007/s12282-017-0813.
    >> Share

    October 2017
  60. ARAKI K, Miyoshi Y
    Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2017 Oct 31. doi: 10.1007/s12282-017-0812.
    >> Share

  61. KHPAL M, Miller JRC, Petrovic Z, Hassanally D, et al
    Local anesthetic delivery via surgical drain provides improved pain control versus direct skin infiltration following axillary node dissection for breast cancer.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0810.
    >> Share

  62. REGEV-AVRAHAM Z, Baron-Epel O, Hammond SK, Keinan-Boker L, et al
    Passive smoking, NAT2 polymorphism, and breast cancer risk in Israeli Arab women: a case-control study.
    Breast Cancer. 2017 Oct 26. doi: 10.1007/s12282-017-0809.
    >> Share

  63. OGITA M, Nagura N, Kawamori J, In R, et al
    Risk factors for complications among breast cancer patients treated with post-mastectomy radiotherapy and immediate tissue-expander/permanent implant reconstruction: a retrospective cohort study.
    Breast Cancer. 2017 Oct 19. doi: 10.1007/s12282-017-0808.
    >> Share

  64. TOYODA Y, Tabuchi T, Nakayama T, Hojo S, et al
    Trends in the clinical stage distribution of breast cancer in Osaka, Japan.
    Breast Cancer. 2017 Oct 12. doi: 10.1007/s12282-017-0807.
    >> Share

    September 2017
  65. ALTUNDAG K
    Questions about lower inner zone tumors in early-stage breast cancer.
    Breast Cancer. 2017 Sep 14. doi: 10.1007/s12282-017-0801.
    >> Share

    August 2017
  66. HATTORI M, Ishiguro H, Masuda N, Yoshimura A, et al
    Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
    Breast Cancer. 2017 Aug 31. doi: 10.1007/s12282-017-0798.
    >> Share

  67. YAMAGUCHI T, Mukai H, Akiyama F, Arihiro K, et al
    Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer.
    Breast Cancer. 2017 Aug 30. doi: 10.1007/s12282-017-0799.
    >> Share

  68. YANG J, Tang S, Zhou Y, Qiu J, et al
    Prognostic implication of the primary tumor location in early-stage breast cancer: focus on lower inner zone.
    Breast Cancer. 2017 Aug 18. doi: 10.1007/s12282-017-0797.
    >> Share

    July 2017
  69. YU Z, Guo X, Jiang Y, Teng L, et al
    Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.
    Breast Cancer. 2017 Jul 28. doi: 10.1007/s12282-017-0794.
    >> Share

  70. NAKAMURA R, Yamamoto N, Miyaki T, Itami M, et al
    Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer.
    Breast Cancer. 2017 Jul 22. doi: 10.1007/s12282-017-0795.
    >> Share

  71. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Erratum to: Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jul 7. doi: 10.1007/s12282-017-0792.
    >> Share

    June 2017
  72. NAKAI K, Xia W, Liao HW, Saito M, et al
    The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Breast Cancer. 2017 Jun 22. doi: 10.1007/s12282-017-0790.
    >> Share

  73. SEKIGUCHI K
    Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction.
    Breast Cancer. 2017 Jun 14. doi: 10.1007/s12282-017-0788.
    >> Share

  74. YU X, Zhou S, Wang J, Zhang Q, et al
    Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies.
    Breast Cancer. 2017 Jun 10. doi: 10.1007/s12282-017-0789.
    >> Share

  75. TADA K, Nishioka K, Kikuchi Y, Niwa T, et al
    Post-mastectomy radiation therapy in breast cancer with 1-3 involved lymph nodes: the Pros.
    Breast Cancer. 2017 Jun 5. doi: 10.1007/s12282-017-0787.
    >> Share

    May 2017
  76. MIZOTA Y, Ohashi Y, Iwase T, Iwata H, et al
    Rainbow of KIBOU (ROK) study: a Breast Cancer Survivor Cohort in Japan.
    Breast Cancer. 2017 May 25. doi: 10.1007/s12282-017-0784.
    >> Share

  77. MATSUDA N, Kida K, Ohde S, Suzuki K, et al
    Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
    Breast Cancer. 2017 May 23. doi: 10.1007/s12282-017-0782.
    >> Share

  78. TOMIOKA N, Azuma M, Ikarashi M, Yamamoto M, et al
    The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Breast Cancer. 2017 May 9. doi: 10.1007/s12282-017-0781.
    >> Share

    April 2017
  79. LEUTERITZ K, Weissflog G, Barthel Y, Brahler E, et al
    Therapeutic alliance and treatment outcome in psychodynamic psychotherapy of depressed breast cancer patients: the same old story or different from other populations?
    Breast Cancer. 2017 Apr 28. doi: 10.1007/s12282-017-0777.
    >> Share

  80. YAMAMOTO S, Maeda N, Nagashima Y, Kubo H, et al
    A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Breast Cancer. 2017 Apr 24. doi: 10.1007/s12282-017-0779.
    >> Share

  81. KITAYAMA H, Kondo T, Sugiyama J, Kurimoto K, et al
    High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
    Breast Cancer. 2017 Apr 22. doi: 10.1007/s12282-017-0778.
    >> Share

  82. GHEYBI MK, Farrokhi S, Ravanbod MR, Ostovar A, et al
    The correlation of CD19 + CD24 + CD38 + B cells and other clinicopathological variables with the proportion of circulating Tregs in breast cancer patients.
    Breast Cancer. 2017 Apr 20. doi: 10.1007/s12282-017-0775.
    >> Share

  83. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Breast Cancer. 2017 Apr 19. doi: 10.1007/s12282-017-0774.
    >> Share

  84. HANAMURA T, Hayashi SI
    Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
    Breast Cancer. 2017 Apr 7. doi: 10.1007/s12282-017-0772.
    >> Share

  85. MALEK-HOSSEINI Z, Jelodar S, Talei A, Ghaderi A, et al
    Elevated Syndecan-1 levels in the sera of patients with breast cancer correlate with tumor size.
    Breast Cancer. 2017 Apr 5. doi: 10.1007/s12282-017-0773.
    >> Share

  86. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2017 Apr 4. doi: 10.1007/s12282-017-0771.
    >> Share

    March 2017
  87. LIN WZ, Xu QN, Wang HB, Li XY, et al
    Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials.
    Breast Cancer. 2017 Mar 21. doi: 10.1007/s12282-017-0770.
    >> Share

  88. ALTUNDAG K
    Robust predictive markers are needed for early detection of trastuzumab-related cardiac dysfunction in breast cancer.
    Breast Cancer. 2017 Mar 8. doi: 10.1007/s12282-017-0767.
    >> Share

  89. GALLI G, Tessari A, Di Cosimo S
    Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.
    Breast Cancer. 2017 Mar 6. doi: 10.1007/s12282-017-0766.
    >> Share

    February 2017
  90. KOGA C, Akiyoshi S, Ishida M, Nakamura Y, et al
    Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
    Breast Cancer. 2017 Feb 27. doi: 10.1007/s12282-017-0764.
    >> Share

  91. UOMORI T, Horimoto Y, Mogushi K, Matsuoka J, et al
    Relationship between alcohol metabolism and chemotherapy-induced emetic events in breast cancer patients.
    Breast Cancer. 2017 Feb 20. doi: 10.1007/s12282-017-0761.
    >> Share

  92. ALTUNDAG K
    Does longer disease-free interval affect the complete remission in metastatic breast cancer?
    Breast Cancer. 2017 Feb 16. doi: 10.1007/s12282-017-0762.
    >> Share

    January 2017
  93. KOIKE Y, Ohta Y, Saitoh W, Yamashita T, et al
    Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Breast Cancer. 2017 Jan 31. doi: 10.1007/s12282-017-0757.
    >> Share

  94. LUO M, Ding L, Li Q, Yao H, et al
    miR-668 enhances the radioresistance of human breast cancer cell by targeting IkappaBalpha.
    Breast Cancer. 2017 Jan 30. doi: 10.1007/s12282-017-0756.
    >> Share

  95. INOUE M, Nakagomi H, Nakada H, Furuya K, et al
    Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Breast Cancer. 2017 Jan 20. doi: 10.1007/s12282-017-0753.
    >> Share

  96. ISHIKAWA T, Kaise H, Yamada K, Hosonaga M, et al
    Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-016-0749.
    >> Share

  97. TANAKA S, Suzuki K, Sakaguchi M
    The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
    Breast Cancer. 2017 Jan 9. doi: 10.1007/s12282-017-0752.
    >> Share

  98. GALLI G, Tessari A, Porcu L, Bregni G, et al
    Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-017-0751.
    >> Share

  99. HALLAJIAN Z, Mahjoubi F, Nafissi N
    Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Breast Cancer. 2017 Jan 5. doi: 10.1007/s12282-016-0750.
    >> Share

  100. FUTAMURA M, Nagao Y, Ishihara K, Takeuchi M, et al
    Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Breast Cancer. 2017 Jan 3. doi: 10.1007/s12282-016-0748.
    >> Share

  101. SUGIE T, Toi M
    Antitumor immunity and advances in cancer immunotherapy.
    Breast Cancer. 2017;24:1-2.
    >> Share

    December 2016
  102. PARK JH
    The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial.
    Breast Cancer. 2016 Dec 23. doi: 10.1007/s12282-016-0747.
    >> Share

    November 2016
  103. VELAEI K, Samadi N, Soltani S, Barazvan B, et al
    NFkappaBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Breast Cancer. 2016.
    >> Share

  104. LI T, Liu Y, Xiao H, Xu G, et al
    Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer.
    Breast Cancer. 2016.
    >> Share

  105. HOSSAIN A, Murshid GM, Zilani MN, Islam F, et al
    TP53 codon 72 polymorphism and breast cancer risk in Bangladeshi population.
    Breast Cancer. 2016.
    >> Share

  106. GUVELI H, Guveli ME, Sen F, Oflaz S, et al
    Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer.
    Breast Cancer. 2016.
    >> Share

  107. IMAMURA T, Yamamoto-Ibusuki M, Sueta A, Kubo T, et al
    Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
    Breast Cancer. 2016;23:876-885.
    >> Share

  108. YAMASHITA H, Ogiya A, Shien T, Horimoto Y, et al
    Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer. 2016;23:830-843.
    >> Share

  109. SHIMO A, Tsugawa K, Tsuchiya S, Yoshie R, et al
    Oncologic outcomes and technical considerations of nipple-sparing mastectomies in breast cancer: experience of 425 cases from a single institution.
    Breast Cancer. 2016;23:851-860.
    >> Share

    October 2016
  110. MARUTHANILA VL, Elancheran R, Kunnumakkara AB, Kabilan S, et al
    Recent development of targeted approaches for the treatment of breast cancer.
    Breast Cancer. 2016.
    >> Share

  111. TANE K, Egawa C, Takao S, Yamagami K, et al
    Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
    Breast Cancer. 2016.
    >> Share

  112. TAN T, Zhang K, Chen W
    Erratum to: Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    >> Share

  113. YANG J, Tan Q, Fu Q, Zhou Y, et al
    Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications.
    Breast Cancer. 2016.
    >> Share

    September 2016
  114. NAKADA H, Nakagomi H, Hirotsu Y, Amemiya K, et al
    A study of tumor heterogeneity in a case with breast cancer.
    Breast Cancer. 2016.
    >> Share

  115. OGIYA A, Yamazaki K, Horii R, Shien T, et al
    Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer.
    Breast Cancer. 2016.
    >> Share

  116. UEMATSU T
    Possible supplemental breast cancer screening modalities.
    Breast Cancer. 2016.
    >> Share

    August 2016
  117. ZHANG X, Fan Y, Liu B, Qi X, et al
    Med19 promotes breast cancer cell proliferation by regulating CBFA2T3/HEB expression.
    Breast Cancer. 2016.
    >> Share

  118. IKEDA T, Sugie T, Shimizu A, Toi M, et al
    Patterns of clinical practice for sentinel lymph node biopsy in women with node-negative breast cancer: the results of a national survey in Japan.
    Breast Cancer. 2016.
    >> Share

  119. SAKAKIBARA J, Sakakibara M, Shiina N, Fujimori T, et al
    Expression of cell polarity protein scribble differently affects prognosis in primary tumor and lymph node metastasis of breast cancer patients.
    Breast Cancer. 2016.
    >> Share

  120. IMOTO S, Yamauchi C, Komoike Y, Tsugawa K, et al
    Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society.
    Breast Cancer. 2016.
    >> Share

  121. HSIEH WC, Lin C, Chen DR, Yu WF, et al
    Genetic polymorphisms in APE1 Asp148Glu(rs3136820) as a modifier of the background levels of abasic sites in human leukocytes derived from breast cancer patients and controls.
    Breast Cancer. 2016.
    >> Share

  122. LI J, Ren J, Sun W
    Systematic review of ixabepilone for treating metastatic breast cancer.
    Breast Cancer. 2016.
    >> Share

    July 2016
  123. ANDRYSZAK P, Wilkosc M, Zurawski B, Izdebski P, et al
    Verbal fluency in breast cancer patients treated with chemotherapy.
    Breast Cancer. 2016.
    >> Share

  124. TAN T, Zhang K, Sun WC
    Genetic variants of ESR1 and SGSM3 are associated with the susceptibility of breast cancer in the Chinese population.
    Breast Cancer. 2016.
    >> Share

    June 2016
  125. NAGATA T, Shimada Y, Sekine S, Moriyama M, et al
    KLF4 and NANOG are prognostic biomarkers for triple-negative breast cancer.
    Breast Cancer. 2016.
    >> Share

  126. EICHLER M, Singer S, Janni W, Harbeck N, et al
    Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial.
    Breast Cancer. 2016.
    >> Share

  127. UEMATSU T
    The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan.
    Breast Cancer. 2016.
    >> Share

  128. PORDELI M, Nakhjiri M, Safavi M, Ardestani SK, et al
    Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
    Breast Cancer. 2016.
    >> Share

    May 2016
  129. HONDA K, Takeshita K, Murotani K, Mitsuma A, et al
    Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer.
    Breast Cancer. 2016.
    >> Share

  130. MORIYA T
    The current topics of surgical pathology of breast cancer in Japan.
    Breast Cancer. 2016.
    >> Share

  131. KACZYNSKA A, Herman-Antosiewicz A
    Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.
    Breast Cancer. 2016.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016